XML 22 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Stockholders' Equity
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
7
.     
Stockholders
Equity
 
Common Stock
On
March 28, 2018,
the Company sold
609,636
shares of common stock at a price of
$2.27
per share.  The net proceeds to the Company from the sale and issuance of the shares, after deducting the offering expenses borne by the Company of approximately
$171,000,
were
$1,213,000.
  Additionally, the investors received unregistered warrants in a simultaneous private placement to purchase up to
304,818
shares of common stock.  The warrants have an exercise price of
$2.68
per share and shall be exercisable commencing
six
months following the issuance date and have a term of
5.5
years.
 
Stock Based Compensation
The Company recorded stock-based compensation of
$137,000
and
$247,000
for the
three
months ended
March 31, 2018
and
2017,
respectively.
 
The following is a summary of option activity for the Company’s stock option plans:
 
   
Number of
Shares
   
Weighted-
Average
Exercise
Price
   
Weighted-
Average
Remaining
Contractual
Life
   
Aggregate
Intrinsic
Value
 
                                 
Outstanding at December 31, 2017
   
1,156,027
    $
3.92
     
 
     
 
 
                                 
Granted
   
80,000
    $
3.00
     
 
     
 
 
Forfeited
   
(2,435
)   $
3.53
     
 
     
 
 
Expired
   
(27,182
)   $
4.67
     
 
     
 
 
                                 
Outstanding at March 31, 2018
   
1,206,410
    $
3.84
     
8.5
     
--
 
                                 
Vested and expected to vest at March 31, 2018
   
943,103
    $
4.07
     
8.3
     
--
 
                                 
Exercisable at March 31, 2018
   
306,582
    $
6.22
     
5.7
     
--
 
 
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were
no
options exercised during the
three
months ended
March 31, 2018.
 
The fair value of the Company’s stock options granted for the
three
months ended
March 31, 2018
was estimated using the following weighted-average assumptions:
 
Expected life (years)
   
5.6
 
Risk-free interest rate
   
2.7
%
Expected volatility
   
98
%
Dividend yield
   
0
%
 
Common Stock Restricted
Units
The following is a summary of restricted stock activity during the
three
months ended
March 31, 2018:
 
           
Weighted
Average
 
   
Number of
Shares
   
Grant Date
Fair Value
 
Balance at December 31, 2017
   
416
    $
17.60
 
Granted
   
--
     
 
 
Vested
   
--
     
 
 
Forfeited
   
--
     
 
 
Outstanding at March 31, 2018
   
416
    $
17.60
 
 
Warrants
A summary of warrant activity for the
three
months ended
March 31, 2018
follows:
 
   
Number of
Shares
   
Weighted-Average
Exercise Price Per
Share
 
Balance at December 31, 2017
   
4,828,723
    $
9.37
 
Warrants granted
   
304,818
     
2.68
 
Warrants canceled
   
--
     
--
 
Warrants exercised
   
--
     
--
 
                 
Outstanding at March 31, 2018
   
5,133,541
    $
8.97
 
                 
Exercisable at March 31, 2018
   
4,130,194
    $
9.60
 
 
At
March 31, 2018,
the total intrinsic value of warrants outstanding and exercisable was
$0
.